< Back to Press

ASCENSIA DIABETES CARE EXPANDS STRATEGIC ALLIANCE WITH INSULET CORPORATION BY SIGNING COMMERCIAL AGREEMENT

Basel, Switzerland

Ascensia Diabetes Care today announced it has expanded the scope of its strategic alliance with Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology, by signing a global commercial agreement. This follows the worldwide non-exclusive development agreement that Ascensia announced in June 2017 to connect its CONTOUR^®NEXT ONE blood glucose monitoring system (BGMS) with Insulet’s next-generation Omnipod System (Omnipod DASH). 

Under the terms of this non-exclusive commercial agreement, Insulet will distribute the CONTOUR^®NEXT ONE BGMS with the Omnipod DASH^™️. Recipients of Omnipod DASH^™️ will receive the CONTOUR^®NEXT ONE meter and CONTOUR^®NEXT test strips packaged with their insulin pump.

The CONTOUR^®NEXT ONE BGMS will pair, via Bluetooth Low Energy (BLE), with the Omnipod DASH^™️ Personal Diabetes Manager (Omnipod DASH^™️ PDM) to transmit a person’s blood glucose readings directly into the system. These readings will be used by the Omnipod DASH^™️ PDM to calculate insulin dosing.

“I am excited to announce this commercial agreement as the next step in our strategic alliance with Insulet. This agreement allows people with diabetes who choose Omnipod DASH^™️ to receive Ascensia’s CONTOUR NEXT ONE meter and test strips to connect to Insulet’s pump,” said Michael Kloss, CEO, Ascensia Diabetes Care.

Michael added, “We believe this strategic alliance with Insulet will help us to further establish ourselves as the partner of choice for blood glucose monitoring in the insulin pump sector.”

The CONTOUR^®NEXT ONE BGMS received 510(k) clearance from the FDA in November 2016 and has been shown to meet the stricter accuracy requirements of the FDA Over-the-Counter BGMS Guidance that was recently issued in 2016. In a clinical study, 95% of blood glucose results obtained with the CONTOUR^®NEXT ONE BGMS were within 8.4 mg/dL (0.5 mmol/L) or 8.4% of the reference result for subject fingertip tests.¹

The CONTOUR^®NEXT ONE BGMS includes a smartLIGHT^™️ feature that provides instant feedback on blood glucose results. The meter compares the actual test results with target levels and illuminates the strip port green for results within target range, yellow for above target range and red for below target range. The system also includes Second-Chance^® sampling that prompts patients to reapply blood to the test strip within 60 seconds if the first sample is insufficient, helping to avoid the wasting of strips.

ENDS

Notes for Editors

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR^® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 30 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

About Insulet Corporation

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and www.omnipodeurope.com.*

*Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.

© 2017 Ascensia Diabetes Care. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

For further information, please contact:
Joseph Delahunty
Ascensia Diabetes Care
joseph.delahunty@ascensia.com
Tel: +41 79 422 9286

References

1. Christiansen et al. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society, October 22-24, 2015, Bethesda, Maryland.